☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
viiv healthcare
ViiV Healthcare, GSK & Pfizer’s Global Specialist HIV Company, Reports P-III (LATITUDE) Study Results of Cabenuva (cabotegravir +...
February 21, 2024
ViiV Healthcare's Vocabria in Combination with Rekambys Receives the NMPA’s Approval as an HIV-1 Injectable Treatment
October 26, 2023
ViiV Healthcare’s Apretude (cabotegravir long-acting injectable and tablets) Receives EC’s Approval for HIV Prevention
September 19, 2023
ViiV Healthcare Receives EMA’s CHMP Positive Opinion of Cabotegravir for HIV Prevention
July 24, 2023
Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva
May 19, 2023
ViiV Healthcare Receives EC's Marketing Authorisation of Triumeq PD for the Treatment of Human Immunodeficiency Virus Type 1
February 22, 2023
Load more...
Back to Home